Biodesix Cites 'Natural Fit' Of Acquired Integrated Diagnostics Lung Cancer Test

Biodesix has acquired Integrated Diagnostics for an undisclosed sum to add the XL2 lung-cancer test to its molecular diagnostics line-up and to acquire technology and expertise that can improve its biopharma business.

MT1807_Lung-Xray_283602125_1200.jpg
• Source: shutterstock.com

Biodesix Inc. is acquiring Integrated Diagnostics Inc. (Indi) for both its flagship XL2 lung-cancer test and to upgrade its ability to develop new pharma companion diagnostics. Terms of the deal, announced July 9, were not disclosed.

"That is perfect for us, because our primary call point is the pulmonologist and this is one of the big...

More from Deals

More from Business